BN Business News
Add your company to Business Communicator →

Business · 01/07/2016Updated: 10/17/2026 · 1 min read

FDA Announces Public Workshop on Erythropoietic Protoporphyria to Discuss Potential Drug Therapies

Summary

The FDA is hosting a public workshop to gather input from patients, healthcare providers, and industry experts on developing safe and effective treatments for Erythropoietic Protoporphyria, a condition that affects daily life, and to discuss the clinical development of potential therapies.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →